Trial Profile
Prospective, non-randomized, single-centre, observational study investigating the safety and efficacy of dabigatran and rivaroxaban compared to Vitamin K antagonists in atrial fibrillation patients undergoing catheter ablation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Vitamin K antagonists
- Indications Embolism; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- 05 Dec 2015 New trial record